230-RICR-20-30-14
A. As used in this Part:
1. "Adverse benefit determination" means a decision not to authorize a health care service, including a denial, reduction, or termination of, or a failure to provide or make a payment, in whole or in part, for a benefit. A decision by a review agent to authorize a health care service in an alternative setting, a modified extension of stay, or an alternative treatment shall not constitute an adverse benefit determination if the review agent and provider are in agreement regarding the decision. Adverse benefit determinations include:
6. "Benefit determination" means a decision to approve or deny a request to provide or make payment for a health care service or treatment. Benefit determinations include:
24. "Material change" means a systemic change determined by the Office to be a change, that could reasonably be expected to adversely affect the access, availability, quality or continuity of services for a significant number of beneficiaries of a health care entity to include, but not be limited to the following:
40. "Utilization review" or “non-administrative review” means the prospective, concurrent, or retrospective assessment of the medical necessity and/or appropriateness of the allocation of health care services of a provider, given or proposed to be given, to a beneficiary. Utilization review does not include:
B. A review agent operating in Rhode Island shall provide evidence of adherence to the following:
D. The cost of the application processes (certification, recertification, and material change), application reviews, complaint processing, investigations, and other activities related to obtaining and maintaining review agency certifications shall be borne by the review agents, as determined by the Commissioner, including:
F. Review agents must maintain and submit to the Office its most current grievance and complaint process that adheres to and includes the following minimal requirements:
B. Each agency must maintain regular and meaningful oversight of each of its delegates to ensure every such delegate is in compliance with the Act's requirements, including but not limited to the following:
A. Each review agent must submit to the Office its policies and procedures in accordance with the Act that evidence adherence to the following:
2. In the event of a failure by a claimant to follow the health care entity’s claims procedures for a pre-service claim, the health care entity or its review agent must comply with notification provisions in accordance with R.I. Gen. Laws § 27-18.9-5(a) and this Part.
a. For non-urgent and non-emergent pre-service claims:
b. Notwithstanding the above, if the pre-service claim relates to urgent or emergent health care services:
B. In accordance with R.I. Gen. Laws Chapter 27-18.9 and this Part, review agents conducting utilization review shall comply with the following:
2. Review agents conducting utilization review are not prohibited from allowing appropriately qualified review agency staff from engaging in discussions with the attending provider, in accordance with the following:
b. Such a discussion prior to any adverse benefit determination may result in a voluntary modification of the attending provider’s original request which shall not constitute an adverse benefit determination provided the following occurred and was documented by the review agent:
3. A review agent shall not retrospectively deny authorization for health care services provided to a beneficiary when an authorization had been obtained for that service from the review agent unless:
4. A review agent shall comply with the following notification timeline requirements in accordance with this Part:
a. For urgent or emergent health care service claims, benefit determinations (adverse or non-adverse) shall be made;
b. For concurrent claims;
c. For pre-service claims, benefit determinations (adverse or non-adverse) shall be made:
(4) The above time parameters set forth in § 14.6(B)(4)(c)((3)) of this Part may be extended for up to fifteen (15) additional calendar days:
d. For post-service claims, benefit determinations (adverse or non-adverse) shall be made:
(2) The above time parameters set forth in § 14.6(B)(4)(d)((1)) of this Part may be extended for up to fifteen (15) additional calendar days:
5. In the event where there is insufficient information from a claimant for the agency to make a utilization review determination, the agency shall adhere to or ensure conditions in accordance with R.I. Gen. Laws § 27-18.9-6(a)(5) and this Part.
D. In accordance with R.I. Gen. Laws § 27-18.9-7 and this Part, review agents making utilization review decisions shall evidence to the Commissioner and comply with the following:
3. Establish and employ a process to transparently incorporate and consider local variations to national standards and criteria identified in this Part including, without limitation, a process to incorporate input from local participating providers. As used in this Part, a process to incorporate and consider local variations to national standards and criteria shall mean a process that:
E. Review agent notifications form and content requirements:
B. All review agents shall conform and evidence to the Commissioner the following for the internal appeal of administrative and non-administrative (utilization review) adverse benefit determinations:
C. When a review agent adopts a policy to incorporate a process to perform a reconsideration to assess an adverse benefit determination, it must comply with the following:
D. Prior to a final internal appeal decision, the review agent must:
G. For administrative appeals the review agent shall notify, in writing, the claimant of its decision:
H. For utilization review appeals, the review agent shall notify, in writing, the claimant of its decision on the utilization review internal appeal:
I. The review agent shall also provide for an expedited appeal process that takes into consideration medical exigencies according to the following:
K. For a request for coverage of a drug that is not on the formulary, the review agent shall complete the internal appeal determination and notify the claimant of its determination according the following:
O. When a utilization review adverse determination is made on internal appeal or reconsideration, including determinations with regard to whether a particular service, treatment, drug, or other item is experimental, investigational or not medically necessary or appropriate, the review agent must adhere to the following:
P. The review agent conducting utilization review must ensure that the appropriate peer reviewer making the internal appeal decision is reasonably available to review the case and must conform to the following:
3. Peer reviewers making an internal appeal decision shall respond to and reasonably accommodate a provider's request for the equivalent two-way, direct communication required by law prior to the internal level of appeal decision, as well as any additional provider request for a two-way direct communication with a peer reviewer in accordance with R.I. Gen. Laws §§ 27-18.9-7(b)(4) and 27-18.9-7(b)(5) and this Part.
B. In order to seek an external appeal;
K. The health care entity and the review agent must ensure that the external appeal process shall include, but not be limited to, the following characteristics:
2. Pursuant to R.I. Gen. Laws § 27-18.9-8(b)(2), the IRO must notice the claimant of its external appeal decision to uphold or overturn the review agency decision:
L. When a utilization review determination is made on external appeal, including determinations with regard to whether a particular service, treatment, drug, or other item is experimental, investigational or not medically necessary or appropriate, the IRO must adhere to the following:
M. For an external appeal of an internal appeal decision of a non-formulary drug, the health care entity and the review agent must ensure that the IRO completes the external appeal determination and notifies the claimant of its determination:
A. Each agency shall compile and maintain reports in form and content consistent with instructions issued as a bulletin by the Office for that purpose and these reports shall: